Marina Chiara Garassino to Europe
This is a "connection" page, showing publications Marina Chiara Garassino has written about Europe.
Connection Strength
0.237
-
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. J Immunother Cancer. 2021 04; 9(4).
Score: 0.043
-
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy. Clin Lung Cancer. 2021 03; 22(2):e180-e192.
Score: 0.042
-
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol. 2020 10; 31(10):1320-1335.
Score: 0.041
-
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score =50% treated with front-line pembrolizumab. Acta Oncol. 2020 Sep; 59(9):1058-1063.
Score: 0.041
-
Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly. Eur Respir J. 2018 02; 51(2).
Score: 0.035
-
Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting. Eur J Surg Oncol. 2019 01; 45(1):75-80.
Score: 0.035